N. Cataldo, F. Abbasi, T. McLaughlin
Nov 1, 2001
Citations
1
Influential Citations
60
Citations
Quality indicators
Journal
Fertility and sterility
Abstract
OBJECTIVE To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS). DESIGN Case report. SETTING Academic clinical practice and General Clinical Research Center. PATIENT(S) A 25-year-old woman with PCOS. INTERVENTION(S) Rosiglitazone maleate, 4 mg daily for 5 months until conception. MAIN OUTCOME MEASURE(S) Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images. RESULT(S) Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception. CONCLUSION(S) Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.